IL112637A - Pharmaceutical preparations containing oxybutynin and methods for its preparation - Google Patents

Pharmaceutical preparations containing oxybutynin and methods for its preparation

Info

Publication number
IL112637A
IL112637A IL11263795A IL11263795A IL112637A IL 112637 A IL112637 A IL 112637A IL 11263795 A IL11263795 A IL 11263795A IL 11263795 A IL11263795 A IL 11263795A IL 112637 A IL112637 A IL 112637A
Authority
IL
Israel
Prior art keywords
sustained release
oxybutynin
dosage form
weight
gum
Prior art date
Application number
IL11263795A
Other languages
English (en)
Hebrew (he)
Other versions
IL112637A0 (en
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22766272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of IL112637A0 publication Critical patent/IL112637A0/xx
Publication of IL112637A publication Critical patent/IL112637A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11263795A 1994-03-04 1995-02-14 Pharmaceutical preparations containing oxybutynin and methods for its preparation IL112637A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/206,416 US5399359A (en) 1994-03-04 1994-03-04 Controlled release oxybutynin formulations
PCT/US1994/002926 WO1995023593A1 (en) 1994-03-04 1994-03-18 Controlled release oxybutynin formulations

Publications (2)

Publication Number Publication Date
IL112637A0 IL112637A0 (en) 1995-05-26
IL112637A true IL112637A (en) 1999-01-26

Family

ID=22766272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11263795A IL112637A (en) 1994-03-04 1995-02-14 Pharmaceutical preparations containing oxybutynin and methods for its preparation

Country Status (15)

Country Link
US (1) US5399359A (pt)
EP (1) EP0700284B1 (pt)
JP (2) JP3699117B2 (pt)
CN (1) CN1111404C (pt)
AT (1) ATE222753T1 (pt)
AU (1) AU676556B2 (pt)
CA (1) CA2161103C (pt)
DE (1) DE69431247T2 (pt)
DK (1) DK0700284T3 (pt)
ES (1) ES2180574T3 (pt)
FI (1) FI113337B (pt)
HU (1) HUT72981A (pt)
IL (1) IL112637A (pt)
PT (1) PT700284E (pt)
WO (1) WO1995023593A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
ES2141044B1 (es) * 1997-02-26 2001-02-01 Alza Corp Terapia con oxibutinina.
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
MXPA03008292A (es) * 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Formas de dosificacion cronoterapeuticas que contienen glucocorticosteroides.
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030034171A (ko) * 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040265381A1 (en) * 2001-10-08 2004-12-30 Shanghvi Dilip S. Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
EP1652522A4 (en) * 2003-08-04 2008-11-26 Kyorin Seiyaku Kk PROLONGED RELEASE TABLET FOR ORAL ADMINISTRATION
WO2005027843A2 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
JP2007505921A (ja) * 2003-09-19 2007-03-15 ペンウェスト ファーマシューティカルズ カンパニー 遅延放出剤形
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
EP2404605B1 (en) * 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
EP3147075B1 (en) 2005-03-15 2019-08-28 Twister Cleaning Technology AB Method for maintenance of hard surfaces
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
ES2374963T3 (es) 2006-01-05 2012-02-23 Essentialis, Inc. Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20110207718A1 (en) 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
WO2011117884A1 (en) * 2010-03-22 2011-09-29 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
EP2827839B1 (en) 2012-03-20 2019-02-27 Particle Dynamics International, LLC Gelling agent-based dosage form
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
CN113599386A (zh) 2014-11-14 2021-11-05 伊森舍丽斯有限公司 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
AU2016288643A1 (en) 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
DE102015014581A1 (de) * 2015-11-12 2017-05-18 Nele Schmidt Prolamine enthaltende Gele, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS5630485A (en) * 1979-08-21 1981-03-27 Sansho Kk Heat insulation composition for heating and cooling
BE902605A (fr) * 1985-06-06 1985-09-30 Therabel Res S A N V Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
CA1272922A (en) * 1986-06-03 1990-08-21 Peter William Berry Drug delivery device, its preparation and use
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3714074A1 (de) * 1987-04-28 1988-11-10 Hoechst Ag Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4857331A (en) * 1988-03-31 1989-08-15 Warner-Lambert Company Sugarless pectin delivery system
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5207932A (en) * 1989-07-20 1993-05-04 Chubb National Foam, Inc. Alcohol resistant aqueous film forming firefighting foam
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules
JPH04273818A (ja) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd 経皮投与製剤
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
ATE185694T1 (de) * 1992-05-13 1999-11-15 Alza Corp Oxybutynin zur transdermalen verabreichung
JP2646170B2 (ja) * 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs

Also Published As

Publication number Publication date
DE69431247D1 (de) 2002-10-02
WO1995023593A1 (en) 1995-09-08
CA2161103C (en) 1999-12-07
CN1111404C (zh) 2003-06-18
IL112637A0 (en) 1995-05-26
DK0700284T3 (da) 2003-01-06
MX9501193A (es) 1998-07-31
PT700284E (pt) 2003-01-31
FI113337B (fi) 2004-04-15
EP0700284B1 (en) 2002-08-28
US5399359A (en) 1995-03-21
ATE222753T1 (de) 2002-09-15
AU6588894A (en) 1995-09-18
ES2180574T3 (es) 2003-02-16
FI955215A (fi) 1995-11-01
FI955215A0 (fi) 1995-11-01
CA2161103A1 (en) 1995-09-08
JPH09501445A (ja) 1997-02-10
HUT72981A (en) 1996-06-28
DE69431247T2 (de) 2003-01-02
JP2005126444A (ja) 2005-05-19
CN1111507A (zh) 1995-11-15
AU676556B2 (en) 1997-03-13
JP3699117B2 (ja) 2005-09-28
HU9503054D0 (en) 1996-01-29
EP0700284A1 (en) 1996-03-13
EP0700284A4 (en) 1996-11-06

Similar Documents

Publication Publication Date Title
US5399359A (en) Controlled release oxybutynin formulations
AU675370B2 (en) Sustained release formulations for 24 hour release of metoprolol
US20210008063A1 (en) Oxymorphone controlled release compositions
US5399362A (en) Once-a-day metoprolol oral dosage form
US5667801A (en) Sustained release heterodisperse hydrogel systems for insoluble drugs
WO2006094083A1 (en) Controlled release venlafaxine formulations
US20060105035A1 (en) Sustained release heterodisperse hydrogel systems for insoluble drugs
MXPA95001193A (es) Formulaciones de oxibutinina de liberacioncontrolada
MXPA94008792A (en) Sustained release formulations for 24 hours of metopro release
MXPA96000024A (en) Form of oral dosing of metoprolol one time

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed